Back to Health

What Is Dolutegravir and What Is It For?

What Is Dolutegravir and What Is It For?
Bareback Guide 12 January 2026

Dolutegravir is an integrase strand transfer inhibitor and probably the single most widely used antiretroviral in the world. It combines a high barrier to resistance, a relatively clean interaction profile and good tolerability, which is an unusual combination.

What kind of drug is it?

An integrase inhibitor, the newest of the main antiretroviral classes. It arrived after raltegravir and elvitegravir and improved on both, which is why it became the reference point against which newer drugs are measured.

How does it work?

To establish infection, HIV must insert a DNA copy of its genome into the chromosomes of the cell it has entered, using an enzyme called integrase. Dolutegravir blocks the strand transfer step where that insertion actually occurs.

What happens when integration is blocked?

The viral DNA remains loose in the cell and is eventually degraded, unable to direct the production of new virus. Because integration is both essential and irreversible, it is an effective point at which to intervene.

Why is integrase a good target?

Because human cells have no equivalent enzyme. A drug blocking it can be highly specific with few effects on normal cellular processes, which is a large part of why the class is so well tolerated.

What is it used for?

HIV treatment as part of a combination, both for people starting and for people switching. It is also used in some post-exposure prophylaxis regimens, where its rapid action and tolerability are advantages over older options.

Does it need a booster?

No. It maintains useful levels for a full day without anything to slow its breakdown, which avoids the extensive interaction problems that ritonavir and cobicistat create. This is one of its main practical advantages.

What is its resistance barrier?

High. Treatment-emergent resistance is rare, even in people who do not fully suppress, and several mutations must accumulate before activity is meaningfully lost. That robustness is comparable to boosted darunavir.

Why does that matter?

Because it means dolutegravir tolerates imperfect adherence better than most antiretrovirals. It does not make missed doses acceptable, and it does mean the consequences of a lapse are less severe than with a low-barrier drug.

How quickly does it work?

Rapidly. Integrase inhibitors reduce viral load faster than older classes, and many people reach undetectable levels within a few weeks of starting treatment.

Does it cover hepatitis B?

Dolutegravir itself does not. Regimens containing it may, through a lamivudine or tenofovir component. Hepatitis B status is checked before any regimen is chosen, and a combination without that cover would leave it untreated.

What is it available with?

On its own and in several combinations, which distinguishes it from bictegravir. That flexibility means it can be paired with whatever backbone suits your kidney function, hepatitis status and resistance history.

Can it be used in two-drug regimens?

Yes. Dolutegravir with lamivudine, and dolutegravir with rilpivirine, are both established options for suitable people. Reducing the number of drugs reduces long-term exposure without reducing effectiveness where the combination is fully active.

Where does it sit in current practice?

First-line across UK and international guidance, and the backbone of treatment programmes worldwide. Its limitations are the neuropsychiatric effects some people experience and the weight question that applies to the class.

Where does it sit against the alternatives?

Very close to bictegravir on most measures, with more flexibility about what accompanies it. The choice frequently comes down to which combination suits the rest of your situation rather than a difference between the two drugs.

What happens when you start it?

Baseline blood tests first, covering kidney and liver function, lipids, viral load and CD4 count, plus hepatitis status and a resistance test. A follow-up appointment usually comes a few weeks later to check tolerability and early response.

Will you have to take it forever?

HIV treatment continues indefinitely, and what you take changes over the years. Being on dolutegravir now does not commit you to it permanently, and most people are on something different a decade later as options improve.

Does it stop you passing HIV on?

Any regimen that achieves and sustains an undetectable viral load does, including this one. Once suppression is sustained, HIV is not transmitted sexually. That is a property of effective treatment rather than of dolutegravir specifically.